Ischemic stroke is caused by a blood clot that blocks an artery in the brain. When the risk of bleeding is low, the use of anticoagulants to prevent blood clots can improve outcomes. Ace Therapeutics is a stroke-focused preclinical CRO offering clients one-stop anticoagulant drug development services. We have strong capabilities and technologies in the field of stroke.
Direct oral anticoagulant drugs, including dabigatran, rivaroxaban, apixaban, and edoxaban, are commonly used to prevent thromboembolism in various populations. Early use of anticoagulant drugs may reduce the volume of infarcted brain tissue by decreasing the spread of intracerebral arterial thrombus, thereby reducing neurologic deficits and the risk of disability and death in patients with acute ischemic stroke. In addition, anticoagulant drugs may inhibit the formation of new arterial and venous thrombi, thereby reducing the risk of early recurrent thromboembolic stroke, deep vein thrombosis, and pulmonary embolism. Emergency anticoagulant drugs have been used in the treatment of acute ischemic stroke, but their efficacy, type of anticoagulant drug, route of administration, and duration of therapy need further study.
Fig. 1. The association between direct oral anticoagulant concentration upon acute stroke and stroke outcome. (Lin et al., 2023)
Ace Therapeutics offers customized services for the development of anticoagulant drugs for stroke. Our team of experts with years of drug development experience can help you design safe and effective anticoagulant drugs and evaluate their preclinical efficacy in stroke treatment. By integrating innovative approaches such as artificial intelligence and machine learning algorithms, we accelerate the development of stroke anticoagulant drugs by enabling rapid target identification, drug design, and lead compound optimization.
We can identify and validate molecular pathways and proteins that play a key role in stroke thrombosis. Our medicinal chemists use rational drug design strategies to develop small molecules that selectively inhibit the coagulation process. We use our expertise in structure-based drug design, computer-aided drug discovery, and molecular modeling to design molecules with optimal pharmacokinetic and pharmacodynamic properties.
We offer a range of in vitro assays for the evaluation of anticoagulant drugs.
We provide animal stroke models to evaluate the efficacy of anticoagulant drugs. Anticoagulant drugs are administered at the time, dose, and route of administration according to the client's needs. In addition, we can evaluate the brain toxicity and distribution of anticoagulant drugs in the brain.
We can help clients develop different types of anticoagulant drugs. They have predictable pharmacokinetics and pharmacodynamics, a wide therapeutic window, a low dose threshold for efficacy, and a high dose threshold for bleeding complications.
Ace Therapeutics offers customized anticoagulant drug development services to help clients develop safe and effective anticoagulant drugs for stroke. We work closely with our partners to develop a comprehensive strategy that meets their goals and timelines. If you are interested in our services, please do not hesitate to contact us!
We are committed to accelerating progress in stroke research and drug development.